GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (STU:CX5) » Definitions » Notes Receivable

LadRx (STU:CX5) Notes Receivable : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is LadRx Notes Receivable?

LadRx's Notes Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.


LadRx Notes Receivable Historical Data

The historical data trend for LadRx's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Notes Receivable Chart

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LadRx Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


LadRx Notes Receivable Related Terms

Thank you for viewing the detailed overview of LadRx's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


LadRx (STU:CX5) Business Description

Traded in Other Exchanges
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

LadRx (STU:CX5) Headlines

No Headlines